Erika Martinelli
About
Erika Martinelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Erika Martinelli has authored 109 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Erika Martinelli's work include Colorectal Cancer Treatments and Studies (55 papers), Lung Cancer Treatments and Mutations (28 papers) and Gastric Cancer Management and Outcomes (24 papers). Erika Martinelli is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Lung Cancer Treatments and Mutations (28 papers) and Gastric Cancer Management and Outcomes (24 papers). Erika Martinelli collaborates with scholars based in Italy, Spain and United States. Erika Martinelli's co-authors include Fortunato Ciardiello, Floriana Morgillo, Teresa Troiani, Andrés Cervantes, Jean‐Charles Nault, Bruno Sangro, Bruno Daniele, Peter Schirmacher, Arndt Vogel and Jens Ricke and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.
In The Last Decade
Erika Martinelli
105 papers receiving 4.3k citations
Hit Papers
Peers
Erika Martinelli
Alexander Laird United States
Ferry A.L.M. Eskens Netherlands
Chetan Lathia United States
Jianping Xiong China
Henry Q. Xiong United States
T.R. Jeffry Evans United Kingdom
Mario Scartozzi Italy
Yuxian Bai China
Vincenzo Catalano Italy
Tohru Utsunomiya Japan
Citations per year, relative to Erika Martinelli Erika Martinelli (= 1×)
peers
Alexander Laird
Countries citing papers authored by Erika Martinelli
Since
Specialization
Citations
This map shows the geographic impact of Erika Martinelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erika Martinelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erika Martinelli more than expected).
Fields of papers citing papers by Erika Martinelli
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Erika Martinelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erika Martinelli. The network helps show where Erika Martinelli may publish in the future.
Co-authorship network of co-authors of Erika Martinelli
This figure shows the co-authorship network connecting the top 25 collaborators of Erika Martinelli. A scholar is included among the top collaborators of Erika Martinelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erika Martinelli. Erika Martinelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Elez, Élena, Salvatore Siena, Andrea Sartore‐Bianchi, et al.. (2024). A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.. Journal of Clinical Oncology. 42(16_suppl). 3589–3589.
2.
Martini, Giulia, Davide Ciardiello, Stefania Napolitano, et al.. (2023). Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. Frontiers in Oncology. 13. 1069370–1069370.
3.
Ciardiello, Davide, Stefania Napolitano, Vincenzo Famiglietti, et al.. (2023). Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers. 15(7). 2117–2117.
4.
Rizzato, Mario Domenico, Monica Niger, Lorenzo Fornaro, et al.. (2023). P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice. Annals of Oncology. 34. S135–S135.
5.
Zhang, Leilei, Pascual García-Pérez, Erika Martinelli, et al.. (2022). Different fractions from wheat flour provide distinctive phenolic profiles and different bioaccessibility of polyphenols following in vitro digestion. Food Chemistry. 404(Pt A). 134540–134540.
6.
Folprecht, Gunnar, Erika Martinelli, Thibault Mazard, et al.. (2021). Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treatment Reviews. 102. 102301–102301.
7.
Elez, Élena, Javier Ros, Giulia Martini, et al.. (2021). LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors. Annals of Oncology. 32. S226–S227.
8.
Corte, Carminia Maria Della, Vincenza Ciaramella, Claudia Cardone, et al.. (2018). Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Journal of Thoracic Oncology. 13(6). 810–820.
9.
Laterza, Maria Maddalena, Anna Capasso, Valentina Belli, et al.. (2016). The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines. Annals of Oncology. 27. iv21–iv21.
10.
Corte, Carminia Maria Della, Claudio Bellevicine, Giovanni Vicidomini, et al.. (2015). SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. Clinical Cancer Research. 21(20). 4686–4697.
11.
Troiani, Teresa, Stefania Napolitano, Donata Vitagliano, et al.. (2014). Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research. 20(14). 3775–3786.
12.
Morgillo, Floriana, Ferdinando Carlo Sasso, Carminia Maria Della Corte, et al.. (2013). Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines. Clinical Cancer Research. 19(13). 3508–3519.
13.
Troiani, Teresa, Erika Martinelli, Stefania Napolitano, et al.. (2013). Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research. 19(24). 6751–6765.
14.
Troiani, Teresa, Silvia Zappavigna, Erika Martinelli, et al.. (2013). Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on Biological Therapy. 13(2). 241–255.
15.
Baselga, José, Alain C. Mita, Patrick Schöffski, et al.. (2012). Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788. Clinical Cancer Research. 18(22). 6364–6372.
16.
Troiani, Teresa, Loredana Vecchione, Erika Martinelli, et al.. (2012). Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. British Journal of Cancer. 106(10). 1648–1659.
17.
Baselga, José, Andrés Cervantes, Erika Martinelli, et al.. (2010). Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors. Clinical Cancer Research. 16(19). 4876–4883.
18.
Orditura, Michele, Gennaro Galizia, Vincenzo Napolitano, et al.. (2010). Weekly Chemotherapy with Cisplatin and Paclitaxel and Concurrent Radiation Therapy as Preoperative Treatment in Locally Advanced Esophageal Cancer: A Phase II Study. Cancer Investigation. 28(8). 820–827.
19.
Orditura, Michele, Ferdinando De Vita, Giuseppe Catalano, et al.. (2002). Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis. Journal of Interferon & Cytokine Research. 22(11). 1129–1135.
20.
Vita, Ferdinando De, Ciro Romano, Michele Orditura, et al.. (2001). Interleukin-6 Serum Level Correlates with Survival in Advanced Gastrointestinal Cancer Patients but Is Not an Independent Prognostic Indicator. Journal of Interferon & Cytokine Research. 21(1). 45–52.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alexander Laird Breakdown of academic impact, for papers by Ferry A.L.M. Eskens Breakdown of academic impact, for papers by Chetan Lathia Breakdown of academic impact, for papers by Jianping Xiong Breakdown of academic impact, for papers by Henry Q. Xiong Breakdown of academic impact, for papers by T.R. Jeffry Evans Breakdown of academic impact, for papers by Mario Scartozzi Breakdown of academic impact, for papers by Yuxian Bai Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by Tohru Utsunomiya